Opus Genetics (IRD) Total Current Liabilities (2018 - 2026)

Opus Genetics (IRD) has 9 years of Total Current Liabilities data on file, last reported at $9.3 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 61.49% year-over-year to $9.3 million in Q1 2026; TTM through Mar 2026 was $9.3 million, a 61.49% decrease from a year earlier, with the FY2025 full-year figure at $7.8 million, down 31.11% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $9.3 million, up from $7.8 million in the prior quarter.
• Over the last five years, Total Current Liabilities for IRD reached as high as $29.1 million in Q3 2025 and fell as low as $2.7 million in Q3 2022.
• Historically, Total Current Liabilities has averaged $8.7 million across 5 years, with a median of $5.8 million in 2023.
• Across the five-year window, Total Current Liabilities soared 380.99% in 2025 and sank 61.49% in 2026, its largest moves.
• Year by year, Total Current Liabilities stood at $2.8 million in 2022, then surged by 46.82% to $4.0 million in 2023, then surged by 179.44% to $11.3 million in 2024, then tumbled by 31.11% to $7.8 million in 2025, then rose by 20.04% to $9.3 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $9.3 million in Q1 2026, $7.8 million in Q4 2025, and $29.1 million in Q3 2025.